[Long-term treatment of Parkinson's disease patients with selegiline hydrochloride (FPF 1100): outcome of 5-year treatment].
We herein report on the outcome of 5 year-treatment of Parkinson's disease patients with selegiline hydrochloride. The subjects participated in this study were 10 patients whose treatment had been maintained consecutively by administration of this agent even after completion of the Phase II trial (all cases under adjunct therapy with L-DOPA/DCI). The daily dose of selegiline hydrochloride was 6.6 +/- 2.5 mg in average at the end and/or termination of the study. As for L-DOPA, its daily dose decreased from 410 +/- 160 mg to 365 +/- 133 mg at the 6th month, but the dose reduction level after 9 months was not determinable due to an increase in dropouts. Regarding alteration in the scores for individual symptoms, improvement in wearing-off symptom was pronounced during the treatment period of 3 to 51 months. The Global Improvement Rate and Usefulness Rate remained stable during the period of 18 to 30 months treatment although these rates declined after 36 months probably because of exacerbation in disease conditions. This study may assure tolerability of selegiline hydrochloride in a long-term treatment of Parkinson's disease patients.
Kondo
Tomoyoshi
T
Department of Neurology, Juntendo University School of Medicine, Japan.
Takubo
Hideki
H
Yokochi
Fusako
F
Okuma
Yasuyuki
Y
Mizuno
Yoshikuni
Y
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy*; D012642:Selegiline / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline